‘Santen vs. Allergan’ for the top in the xerophthalmia market

Published: 2015-12-22 14:57:31

Updated: 2015-12-22 14:57:31

The xerophthalmia market is experiencing an upheaval. While the 2-strong formation is set among the two originals, the competition for the top is getting fiercer as ‘Diquas’ is about to take over the leading position.

‘Restasis,’ expired in patent last May, recorded significantly lowered sales due to Diquas, generics and incrementally modified drugs.

On the 21^st, Medipana News analyzed the xe...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.